On June 27, 2022 Philogen reported that it will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston (Presentation, Philogen, JUN 27, 2022, View Source [SID1234616283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled "Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)" on the 28 of July.

On June 27, 2022 Dxcover Limited, a clinical stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, reported findings from a new study that shows how Dxcover’s infrared platform detects a solid and clear distinction between cancer and control samples when detecting early stage pancreatic cancer, suggesting a great potential for clinical implementation (Press release, Dxcover, JUN 27, 2022, View Source [SID1234616299]). The data has been published in Cancers. Pancreatic cancer is the seventh leading cause of cancer death and claims more than 460,000 lives per year. It is one of the hardest diseases to detect due to the lack of early symptomatic evidence and fast, simple, and non-invasive diagnostic tests. The carbohydrate antigen (CA) 19-9 test is the blood test used for pancreatic cancer’s detection, but its levels can be raised in symptomatic patients with other non-malignant diseases, or with other tumors in the surrounding area.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dxcover’s proof-of-concept study, investigating the use of attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy on dried blood serum, focused on the discrimination of both cancer versus asymptomatic (healthy) control samples, and cancer versus symptomatic non-malignant control samples, as a novel liquid biopsy approach for pancreatic cancer diagnosis.

Machine learning algorithms were applied, achieving results of 92% sensitivity and 88% specificity when discriminating between cancers (n = 100) and asymptomatic (healthy) controls (n = 100). An area under the curve (AUC) of 0.95 was obtained through receiver operating characteristic (ROC) analysis. In addition, the test identified cancerous patients among a challenging symptomatic cohort to an AUC of 0.83.

"To our knowledge, this is the largest and most promising proof-of-concept study to date for clinical use of ATR-FTIR spectroscopy in the detection of early and advanced stages of pancreatic cancer. The use of our technology can save over $12 million in health care resources per 5000 cancers detected as well rapidly speed up the process for patients to get the required treatment sooner," said Dr. Matthew Baker, Chief Technology Officer and co-founder, Dxcover.

On June 27, 2022 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Press release, Novo Nordisk, JUN 27, 2022, View Source [SID1234616266]). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the programme initiated 3 May 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.

Since the announcement 20 June 2022, the following transactions have been made:

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 15,196,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12- month period beginning 2 February 2022. As of 24 June 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 13,456,818 B shares at an average share price of DKK 757.99 per B share equal to a transaction value of DKK 10,200,072,660

On June 27, 2022 Philogen reported that it will be Bronze Sponsor of the Post-Chicago Meeting in Münich (30-1 July) (Presentation, Philogen, JUN 27, 2022, View Source [SID1234616284]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Philogen will chair a Satellite Symposium on Friday July 1, 11.30-12.00 am. Dr. Alfredo Covelli, Philogen’s CMO, will give a presentation entitled "Immunocytokines for the therapy of cancer: the Philogen Portfolio".

On June 27, 2022 Sanofi K.K. (Head office: Shinjuku-ku, Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku, Tokyo; CEO: Ed Deng) reported that they have entered into a partnering agreement to support healthcare professionals and people living with diabetes mellitus through digital support programs (Press release, Sanofi, JUN 27, 2022, View Source [SID1234616300]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Health2Sync, a digital health startup, specializing in diabetes and other chronic disease management, has developed a healthcare/lifestyle app that has been used by about 290,000 users in Japan. Recently the mean HbA1c level has tended to increase among people living with diabetes mellitus.[i] Patients are receiving an average of 14.8 units of baseline insulin and have an HbA1c of 7.8%, which indicates that the basal insulin dose may be further optimized if an appropriate approach is taken.[ii]

It is not easy for people living with diabetes to continue recording their blood glucose levels to achieve their treatment goals. One of the challenges is that the environment to help them sufficiently control the disease is not fully fostered. Through this partnering agreement, Sanofi and Health2Sync will work together to develop digitized features for healthcare providers and patients on insulin in Japan that will help improve Hypoglycemia/Hyperglycemia insulin management by connected caps for insulin, and titration alerts, to people living with diabetes.

The two companies initiated their collaboration in Taiwan in September 2020 by providing digital health solutions to HCPs and patients and have witnessed a good adoption within more than 200 clinics and more than 10,000 insulin patients having already joined the program as of May 2022.

On this initial traction, Sanofi and Health2Sync announced last year that they will further develop an automated digital insulin management solution with titration algorithms to further enhance the efficiency of insulin treatment. The two companies are collaborating to generate studies on the therapeutic effects of the digital solution.

This agreement in Japan again emphasizes the companies’ ambition to realize a more comprehensive chronic disease management through digital solutions.

Moving forward, Sanofi and Health2Sync plan to further collaborate in bringing innovative digital therapeutics solutions to patients and healthcare professionals in Japan and other markets.